Appointments add two biotech industry veterans each with over two decades of experience to Company's management teamSAN DIEGO, Sept. 01, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced the appointments of Preetam Shah, Ph.D., MBA, as chief financial officer and chief business officer, and Shane Ward as chief legal officer and corporate secretary.…

Top-line data anticipated in late 2021 Single Phase 3 trial serves as basis for global regulatory filings SAN DIEGO and CAMBRIDGE, England, Aug. 17, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX) and Mundipharma today announced that the companies have completed recruitment of the pivotal Phase 3 ReSTORE trial evaluating the efficacy and safety of rezafungin as a potential first-line treatment for candidemia and invasive candidiasis. The trial includes 184 patients diagnosed with candidemia and/or invasive…

SAN DIEGO, Aug. 12, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today reported financial results for the second quarter ended June 30, 2021 and provided an update on its corporate activities and product pipeline. "We began the quarter with the announcement of our worldwide license and collaboration agreement with Janssen for the development and…

SAN DIEGO, Aug. 05, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in a panel discussion at the 2021 Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021. Panel Information:Date:Wednesday, August 11, 2021Time:4:40 PM ETWebcast: A live audio webcast and replay of…

SAN DIEGO, July 27, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present clinical and pre-clinical data, including updated analyses from the Phase 2 STRIVE study and an in vitro evaluation of rezafungin activity against Candida and Aspergillus spp. isolates collected in Asia-Pacific countries, in two presentations at the International…

Oral presentation shows clinical data demonstrating clearance of infection in initial days of treatment of candidemia following one dose of rezafungin compared to multiple daily doses of standard of care Three additional presentations to highlight areas of unmet medical needs to improve treatment of candidemia and invasive candidiasis SAN DIEGO, July 12, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing…

SAN DIEGO, July 07, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that the Compensation Committee of its Board of Directors granted non-qualified stock option awards and restricted stock units for an aggregate of 172,000 shares of its common stock to eight new employees, pursuant to the Cidara Therapeutics, Inc. 2020 Inducement Incentive…

SAN DIEGO, July 01, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that James (Jamie) Levine has resigned from his position as chief financial officer (CFO), effective July 9, 2021, to pursue other opportunities. Mr. Levine will continue to serve as a consultant to the Company for at least six months and will…

SAN DIEGO, June 30, 2021 -- Cidara Therapeutics, Inc. (NASDAQ: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that it will present new analyses in four presentations, including an oral presentation on rezafungin, at the 31st European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), taking place virtually from July 9-12, 2021. Rezafungin is a novel once-weekly echinocandin currently…

SAN DIEGO, June 14, 2021 -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company developing long-acting therapeutics designed to transform the standard of care for patients facing serious fungal or viral infections, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, and James Levine, Chief Financial Officer, will participate in investor meetings at the Raymond James Human Health Innovation Conference, being held virtually June 21-23, 2021. About Cidara TherapeuticsCidara is developing long-acting therapeutics…